Blaustein Robert has filed 4 insider transactions across 1 company since January 2025.
Most recent transaction: a grant/award of 17500 shares of Edgewise Therapeutics, Inc. ($EWTX) on August 12, 2025.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug. 12, 2025 | Edgewise Therapeutics, Inc. | $EWTX | Blaustein Robert | Chief Development Officer | A | Restricted Stock Units | 17500 | $0.00 | 17,500.0000 | 104,940,493 | 9999.99% | 0.02% |
| Aug. 12, 2025 | Edgewise Therapeutics, Inc. | $EWTX | Blaustein Robert | Chief Development Officer | A | Stock Options (Right to buy) | 105000 | $0.00 | 105,000.0000 | 104,940,493 | 9999.99% | 0.10% |
| Jan. 21, 2025 | Edgewise Therapeutics, Inc. | $EWTX | Blaustein Robert | Chief Development Officer | A | Restricted Stock Units | 30000 | $0.00 | 30,000.0000 | 92,414,626 | 9999.99% | 0.03% |
| Jan. 21, 2025 | Edgewise Therapeutics, Inc. | $EWTX | Blaustein Robert | Chief Development Officer | A | Stock Options (Right to buy) | 160000 | $0.00 | 160,000.0000 | 92,414,626 | 9999.99% | 0.17% |